Treatment of lymphangioleiomyomatosis with anastrozole; a potent and selective non-steroidal aromatase inhibitor Source: Eur Respir J 2007; 30: Suppl. 51, 67s Year: 2007
Mycophenolate mofetil: an effective corticosteroid-sparing drug in steroid-dependent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005
JAK inhibitors overcome corticosteroid insensitivity in COPD Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011
From anti-PD1/L1 inhibitors to new immunotherapies Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Mycophenolate mofetil (MMF) rescue therapy in lung transplantation: results and pharmacokinetics Source: Eur Respir J 2002; 20: Suppl. 38, 348s Year: 2002
Comparison of post renal transplant tuberculosis cases receiving conventional immunosupressive therapy and mycophenolat mofetil (MMF) and/or tacrolimus (TAC) Source: Eur Respir J 2003; 22: Suppl. 45, 157s Year: 2003
Standard IS regimens: CNI is still the cornerstone Source: ERS Course 2016 Year: 2016
Effectiveness of inhibitor mTOR in patients with lymphangioleiomyomatosis. Source: International Congress 2018 – New insights in rare diffuse parenchymal lung diseases (DPLDs) in adults and children Year: 2018
Results of switch from mycophenolate mofetil to azathioprin after lung transplantation Source: Eur Respir J 2004; 24: Suppl. 48, 178s Year: 2004
Tolerance to COX-2 inhibitors in patients intolerant to aspirin: challenge mandatory Source: Eur Respir J 2003; 22: Suppl. 45, 547s Year: 2003
Combining corticosteroids and NK1R antagonists: A new drugs combination to treat allergic diseases Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
Emerging inhaled bronchodilators: an update Source: Eur Respir J 2009; 34: 757 Year: 2009
5-lipoxygenase inhibitor therapy in IPF Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Fast, efficient and realistic in vitro delivery of inhaled drugs to pulmonary cells: Application to the proteasome inhibitor bortezomib Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013
The combination of PDE4 and PDE5 inhibitors reduces YAP expression in IPF Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Curcumin in combination with low-dose cyclosporine a in experimental airway transplantation Source: Eur Respir J 2007; 30: Suppl. 51, 518s Year: 2007